Pharmaceutical CDMO Company


  • A CDMO business is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

    Big Pharma companies are increasingly trying to develop alternative options for the US and Europe (given the high cost of manufacturing) and China (given the unpredictability associated with it).
  • Management Commentary: "We see several tailwinds in our business and as we start getting our new capacity on-stream, we expect revenues and profitability to grow faster in next several years. Our strong customer relations, new business opportunities as well as healthy product pipeline will enable us to renew our growth trajectory over the medium to long term."
  • The company is into pharmaceutical sector and is a CDMO player. The company trades at reasonable valuation and hence there is good margin of safety.
  • The company has a long history of decent performance both in terms of sales and operating margins.
  • Over the next 5 years sales are expected to compound at 15% CAGR and reach 3000 crores. As per the management EBIDTA margins will be around 24% which can lead to 350 crores of net profit.
  • P/E of 25 can lead to market capitalization of 8000 crores. Current market capitalization is just 2000 crores.
  • By 2025, we expect the company's stock price to increase by 4 times from the current price.

Note: You can download the report after payment. You can also download the report from the email you will receive. For any help call 9848832694

Popular posts from this blog

Uber like Business Model

Image
Company is an aggregator which is similar to business models like Uber & OYO Rooms. The company has the platform which is much more efficient than the brick & mortar business model. The company is addressing the following problems with traditional business model and hence this industry is ripe for disruption: Inefficient and very high costs and wastage of warehousing and inventory. The rate of obsolescence is high resulting in hard to sell inventory. The completely un-organized industry. The limited reach of the traditional distributors and distribution system. The problem of returns and collections that is ingrained in the retail distribution system The company has tied-up with major e-commerce players like Amazon, Flipkart, etc. Recently the company has expanded its capacity and hence the growth from here on can be steep. Note: You can download the report after payment. You can also download the report from the email you will receive. For any help call 9848832694
Read more

Stock for Short Term Gain of 30% - Free Stock

Image
The company has market cap of 1200 crores out of which 500 crores is cash and 0 debt. You are therefore getting this company for just 700 crores of enterprise value. Profits for this year will be at least 120 crores. Return on Capital Employed is 25%. The company is expected to come out with very good results for December quarter. Due to which in next 3-4 months we expect this stock to give 30% returns from the current level. Also there is a possibility of special dividend for this FY 2021 which can be about 10% of the current stock price. Loading…
Read more